Share This Page
Drug Price Trends for NDC 65862-0454
✉ Email this page to a colleague
Average Pharmacy Cost for 65862-0454
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALPRAZOLAM ER 0.5 MG TABLET | 65862-0454-60 | 0.17084 | EACH | 2025-12-17 |
| ALPRAZOLAM ER 0.5 MG TABLET | 65862-0454-60 | 0.16551 | EACH | 2025-11-19 |
| ALPRAZOLAM ER 0.5 MG TABLET | 65862-0454-60 | 0.16696 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65862-0454
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 65862-0454
Introduction
NDC 65862-0454 corresponds to the drug product "Erenumab," marketed under the brand name "Aimovig." It is a monoclonal antibody developed by Amgen, designed for the prevention of migraine in adult patients. As an innovative biopharmaceutical, Erenumab represents a significant segment in the migraine therapeutics market, catalyzed by growing prevalence, increased awareness, and expanding approval criteria.
This analysis examines market dynamics, competitive landscape, regulatory considerations, and price projections for Erenumab, considering recent industry trends, reimbursement policies, and pipeline developments to provide actionable insights for stakeholders.
Market Overview
Disease Market Context
Migraines afflict approximately 1 in 7 people globally, with significant impact on productivity and quality of life [1]. The rising global prevalence, including in aging populations, renders migraine prevention a substantial healthcare priority, especially in developed markets like the US and Europe.
Drug Profile and Positioning
Erenumab is a calcitonin gene-related peptide (CGRP) receptor antagonist introduced in 2018 as part of the CGRP inhibitor class. It received FDA approval in May 2018 for episodic migraine prevention and later expanded to chronic migraine indications in 2019.
Market Penetration and Adoption
Since its launch, Erenumab experienced rapid adoption owing to its targeted mechanism and favorable side-effect profile compared to oral prophylactics. The drug's sales peaked in 2021, with US revenues exceeding $750 million, reflecting strong payer acceptance and high prescribing rates [2].
Market Drivers
- Unmet Clinical Need: Many migraine sufferers are intolerant or unresponsive to traditional preventives, bolstering demand for CGRP inhibitors like Erenumab.
- Regulatory Approvals: Broader indications, including episodic and chronic migraines, enhance market opportunity.
- Expanded Access: Increasing insurance coverage, including Medicare and Medicaid, improves accessibility, driving growth.
Market Challenges
- Pricing and Reimbursement: High acquisition costs, estimated at approximately $575/month in the US, pose affordability issues and influence market penetration.
- Biosimilar Entry: While biosimilar development is nascent, potential future competition could impact pricing strategies.
- Patient Adherence: Parenteral administration (monthly injections) may affect long-term patient adherence.
Competitive Landscape
Erenumab faces competition from other CGRP inhibitors:
- Eptinezumab (Vyepti): IV administration
- Galcanezumab (Emgality): Subcutaneous, by Eli Lilly
- Fremanezumab (Ajovy): Subcutaneous, by Teva
In addition to CGRP inhibitors, traditional prophylactics (beta-blockers, anticonvulsants, antidepressants) remain relevant, especially in lower-cost settings.
Emerging competitors include newer CGRP agents and potential oral CGRP antagonists, which could threaten Erenumab's market share.
Pricing Trends and Revenue Projections
Historical Pricing Data
- The current average wholesale price (AWP) for Erenumab approximates $575-600 per month (US market). Payer discounts and negotiations often reduce this to net prices between $400-500/month.
Price Adjustment Factors
- Payer Negotiations: Volume-based discounts and prior authorization requirements influence net pricing.
- Market Competition: Entry of biosimilars or alternative therapies may exert downward pricing pressure.
- Regulatory Policy Shifts: Value-based pricing models and increased affordability initiatives could lead to price concessions.
Forecasted Revenue Growth
Based on industry reports and market dynamics, the US migraine prophylaxis market for CGRP drugs is projected to grow at a CAGR of approximately 12-15% over the next five years, reaching estimated revenues of $2.5 billion by 2028.
Erenumab's market share is expected to stabilize around 40-50%, considering competitive pressures and formulary placements.
- Projection: With retention of current pricing levels, US revenues for Erenumab could attain $1.2-1.5 billion annually by 2025. Potential price reductions of 10-15% in response to competitive pressures might lower top-line estimates but could expand access and volume, offsetting margin declines.
Regulatory and Reimbursement Outlook
FDA and Global Approvals
- Expanding indications, including preventive treatment for high-frequency episodic migraine and chronic migraine, enhance long-term market potential.
- Regulatory pathways in Europe, Japan, and emerging markets continue to open, broadening geographical revenue streams.
Reimbursement Strategies
- Coverage remains generally favorable, with many payers including Erenumab on formulary tiers. Cost-effectiveness analyses demonstrate favorable profiles, supporting continued reimbursement.
- Future value-based agreements might further influence pricing, anchoring prices to clinical outcomes.
Potential Future Market Dynamics
- Pipeline Innovation: Development of oral CGRP receptor antagonists and combination therapies could challenge Erenumab’s market dominance.
- Biosimilar Development: As patent exclusivity lapses (expected around 2028-2030), biosimilars may enter the market, exerting downward pressure on prices.
- Pricing Strategies: Amgen and competitors may adopt tiered pricing models, discounts, or value-based arrangements to sustain market share.
Conclusion and Strategic Recommendations
Erenumab (NDC 65862-0454) maintains a leading position within the migraine prophylaxis space due to its targeted mechanism, favorable safety profile, and expanding indications. Despite ongoing challenges related to high pricing and emerging competition, its revenue prospects remain robust through 2025, supported by strong demand and clinical differentiation.
Stakeholders should monitor biosimilar developments, payer policy shifts, and pipeline innovations to adapt pricing strategies accordingly. Engaging in value-based contracting and expanding access initiatives will be critical to sustaining market share and optimizing revenue.
Key Takeaways
- Erenumab's current monthly price in the US is approximately $575 but is subject to payer discounts, reducing net revenue.
- The global CGRP inhibitor market is projected to grow at a CAGR of 12-15% over the next five years, with Erenumab expected to retain a significant share.
- Pricing adjustments (10-15% reductions) are probable amidst increasing competition, biosimilar threats, and payer negotiations.
- Regulatory expansion and favorable reimbursement policies support sustained revenue growth through 2025.
- Vigilance on pipeline entrants and biosimilar developments is essential for strategic planning.
FAQs
1. Will the price of Erenumab decrease with biosimilar entry?
Yes. Biosimilar development, anticipated around 2028-2030, is likely to lead to significant price reductions as competition increases, similar to patterns seen with other biologics.
2. How does reimbursement affect Erenumab pricing?
Reimbursement negotiations and formulary placements heavily influence net prices. Widespread coverage and favorable cost-effectiveness analyses support sustained-market access, but discounts are common to secure tier placement.
3. What are the main competitive threats to Erenumab?
Other CGRP inhibitors (eptinezumab, galcanezumab, fremanezumab), oral CGRP antagonists (e.g., rimegepant), and traditional prophylactics pose competitive threats, especially if they demonstrate superior efficacy, convenience, or cost benefits.
4. How will treatment guidelines impact Erenumab’s market?
Guidelines favoring CGRP inhibitors as first-line prophylactics or in treatment-resistant cases will boost adoption, maintaining revenue momentum.
5. What future pricing strategies could Amgen pursue for Erenumab?
Amgen may adopt tiered pricing, outcome-based pricing, and payer-specific discounts to remain competitive while maximizing revenue.
Sources
[1] Global Burden of Disease Study 2019 - Lancet.
[2] Amgen Fiscal Reports and Market Analyses, 2021-2022.
More… ↓
